[Endoscopic placement of self-expandable metallic stents (Wallstent) for @entity5 , with special reference to preventive endoscopic nasal bile drainage against XXXX after stenting].

@entity1 @entity13404 @entity697 @entity1087 @entity5 @entity648 @entity204 @entity385
From December 1993 to December 1994, we inserted 14 biliary endoprostheses (Wallstent) endoscopically in 12 consecutive @entity1 (5 @entity1 and 7 @entity1 ; 55-91 years [mean 69.8 years] of age) with @entity5 . Successful placement of Wallstent was achieved in all 12 @entity1 . Procedure related @entity204 was encountered in one @entity1 (8.3%) who was complicated with @entity13404 , combined with a slipping migration of the stent. In 11 of the 12 patients, serum @entity648 levels reduced to less than 2.0 mg/dl. @entity697 , which was defined as the obstruction of the stent within 24 hours after the stent placement, occurred in 2 @entity1 (16.7%). Endoscopic nasal bile drainage (ENBD) following stent placement was performed in 4 @entity1 and @entity697 was not developed in these cases. After endoprosthesis 8 @entity1 were discharged with 6-47 hospital days and the average hospitalized period excluding a case with @entity385 was 12.7 days. Excluding one procedure related @entity204 , 6 @entity1 died of primary malignancy 39-189 days (average 90.7 days) after endoprosthesis and in 2 cases recurrence of @entity1087 was observed. The other 4 @entity1 have been alive for 60-174 days (average 102.5 days) without @entity1087 . The survival rate of the all @entity1 was 64% for 3 months and 32% for 6 months, respectively. In conclusion, we suggested that the endoscopic Wallstent placement would contribute to the improvement of the quality of life for @entity1 with @entity5 . However, @entity697 may be developed in some cases. For the purpose of managing @entity697 , we recommend ENBD for a few days following the placement of a Wallstent.
